You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.
Researchers are continuing to collect data on economic, racial, and other factors that could be addressed to make precision medicine access more equitable.
The first stage generated a range of tools and resources for studying the nucleus in time and space including publicly available datasets and software.
The researchers analyzed nearly a dozen new samples from various regions of Vanuatu and different eras in combination with previously published samples.
The company licensed nasopharyngeal swab and toehold switch molecular detection technologies from the Wyss Institute to develop SARS-CoV-2 diagnostics.
The Harvard University spinout uses a combination of proprietary probes, nanoarrays, and convection PCR to target a broad set of molecular biomarkers.
In Science this week: 29 widespread antiviral gene cassettes uncovered, and more.
In Nature this week: chemical-crosslinking assisted proximity capture approach to examine chromatin architecture, and more.
In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.
Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.
The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.
The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.
A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.
In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.